Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 104

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

COVID-19+2

Not recruiting

Study on Everolimus and Mycophenolate Mofetil for Improving COVID-19 Vaccine Response in Kidney Transplant Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Universitair Medisch Centrum Groningen

Pulmonary arterial hypertension

Not recruiting

Study on the Effects of MK-5475 for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:3-(4-{(5S)-4-Amino-2-[6-Chloro-1-(3,3,4,4,4-Pentafluorobutyl)-1H-Indazol-3-Yl]-5-Methyl-6-Oxo6,7-Dihydro-5H-Pyrrolo[2,3-D]Pyrimidin-5-Yl}Phenyl)Propanoic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Post-acute COVID-19 syndrome

Not recruiting

Study on Methylprednisolone for Improving Memory in Patients with Post-COVID-19 Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Colorectal cancer+5

Not recruiting

Study of Subcutaneous Nivolumab with or without Recombinant Human Hyaluronidase PH20 for Patients with Lung, Kidney, Melanoma, Liver, Colorectal, or Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on the Effects of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:UZ Leuven

Bronchiolitis+2

Not recruiting

Study on Oxygen Levels for Children and Adolescents with Respiratory Distress: Focusing on Bronchiolitis, Viral Wheeze, and Lower Respiratory Tract Infection

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Oxygen
  • Sponsor:Spaarne Gasthuis

Non-small cell lung cancer

Not recruiting

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer recurrent

Not recruiting

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Non-small cell lung cancer

Not recruiting

Study of TAS3351 for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:TAS3351
  • Sponsor:Taiho Oncology Inc.

Pulmonary sarcoidosis

Not recruiting

Study on Efzofitimod for Treating Pulmonary Sarcoidosis in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efzofitimod
  • Sponsor:aTYR Pharma Inc.

Cardiac failure+1

Not recruiting

Study of AZD3427 for Patients with Heart Failure and Pulmonary Hypertension from Left Heart Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AZD3427
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.